NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...

The National Institute for Health and Care Excellence (NICE) has recommended darolutamide in combination with androgen ...

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

GSK shares lifted on Monday after the pharmaceutical giant signed a £268m deal with French biotech Syndivia for a potential treatment for prostate cancer.

GSK said it acquired exclusive worldwide rights for a drug candidate targeting prostate cancer from France's Syndivia for up to 268 million pounds ($356.8 million).

The market thrives on precision radiotherapy with growth driven by advanced robotics, non-invasive imaging, and adaptive ...

GSK advanced after saying it had bought the worldwide rights from French biotech firm Syndivia to develop and sell a ...

A major European clinical research event in oncology gives a boost to antibody–drug conjugates, treatments that work like a Trojan horse, delivering chemotherapy to the interior of malignant cells ...

Orphan Drug Designation The purpose of the Orphan Product program is to support the development and evaluation of new treatments for rare diseases. FDA grants Orphan Drug designation to ...